Abstract
The common cold is an important illness both as a result of the economic impact of this common disease and because of the morbidity associated with the complications of the illness. Recent attempts to develop antiviral treatments for the common cold represent a substantial advance over previous efforts. Formidable barriers remain to be overcome, however, before any of these new products will be proven to be clinically useful. Recent advances in our understanding of the pathogenesis of common cold symptoms have provided insights into potential new targets for the treatment of this illness.
MeSH terms
-
3C Viral Proteases
-
Antiviral Agents / therapeutic use*
-
Clinical Trials as Topic
-
Combined Modality Therapy
-
Common Cold / drug therapy*
-
Common Cold / virology
-
Cysteine Endopeptidases / metabolism
-
Dietary Supplements
-
Drug Therapy, Combination
-
Echinacea / therapeutic use
-
Enzyme Inhibitors / therapeutic use
-
Histamine H1 Antagonists / therapeutic use
-
Humans
-
Intercellular Adhesion Molecule-1 / immunology
-
Intercellular Adhesion Molecule-1 / therapeutic use
-
Isoxazoles / therapeutic use
-
Oxadiazoles / therapeutic use
-
Oxazoles
-
Phenylalanine / analogs & derivatives
-
Phytotherapy
-
Picornaviridae Infections / drug therapy*
-
Picornaviridae Infections / virology
-
Plant Extracts / therapeutic use
-
Plants, Medicinal
-
Pyrrolidinones / therapeutic use
-
Receptors, Virus / antagonists & inhibitors
-
Receptors, Virus / immunology
-
Rhinovirus / drug effects*
-
Valine / analogs & derivatives
-
Viral Proteins*
-
Zinc / therapeutic use
Substances
-
Antiviral Agents
-
Enzyme Inhibitors
-
Histamine H1 Antagonists
-
Isoxazoles
-
Oxadiazoles
-
Oxazoles
-
Plant Extracts
-
Pyrrolidinones
-
Receptors, Virus
-
Viral Proteins
-
Intercellular Adhesion Molecule-1
-
Phenylalanine
-
pleconaril
-
Cysteine Endopeptidases
-
3C Viral Proteases
-
Valine
-
Zinc
-
rupintrivir